Our Platform
Our Platform
Our patented, AI-powered platform delivers an end-to-end solution for managing chronic diseases and rapidly addressing emerging infectious threats—from early identification to point-of-care diagnostics and precision therapeutics.
It enables the swift discovery of key molecular drivers behind dysbiotic microbiome states and neutralizes their harmful effects.
At the core of our approach is the data-driven Causal Microbiome Metaproteome Pathways (CMMP) Platform, which constructs a high-resolution map of critical microbiome pathways.
Together, our diagnostic and therapeutic innovations provide effective, personalized, and cost-efficient healthcare solutions.
Our Approach
Our Causal Microbiome Metaproteome Pathways (CMMP) Platform drives our paradigm-shifting vision: chronic diseases can be redefined as specific disturbances in the microbial metaproteome.
Our platform delivers a first-in-class capability to standardize and manage these pathways, providing a powerful new solution to reshape disease treatment and prevention. Unlike traditional approaches, which require discovering or repurposing a separate drug or live biotherapeutic for each condition, our CMMP Platform enables a unified treatment strategy across multiple disorders.
The Evimero Platform provides a complete solution for rapid response to new and emerging infectious diseases from laboratory identification to diagnostic and therapeutic development.
Advantages of the Evimero CMMP Platform…
Streamlined Process
Unlocks dual diagnostic and therapeutic outputs for each disorder in a single streamlined process
Diagnostic & Therapeutic Solutions
Accelerates Discovery Time
Reduce Development Costs
Transformational change in efficiency Reduce therapeutic development costs by two orders of magnitude